This clinical trial is focused on studying Frontotemporal Dementia (FTD), a condition that affects the brain and can lead to changes in behavior and personality, as well as difficulties with language and movement. The study is testing a treatment called latozinemab, also known by its code name AL001. This treatment is given as a solution through an intravenous infusion, which means it is delivered directly into the bloodstream through a vein. The purpose of the study is to evaluate how effective and safe AL001 is for individuals who are at risk for or have FTD due to specific genetic changes, known as heterozygous mutations in the progranulin gene.

Participants in the study will be randomly assigned to receive either the AL001 treatment or a placebo, which is a sterile solution that looks like the treatment but does not contain the active substance. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are not influenced by expectations or bias. The study will take place over a period of time, with participants receiving the treatment or placebo and undergoing regular assessments to monitor their condition and any changes that occur.

The trial aims to measure changes in participants’ symptoms and overall condition at various points during the study, specifically at weeks 48, 72, and 96. These assessments will help determine the effectiveness of AL001 in managing the symptoms of FTD and its impact on participants’ quality of life. The study will also monitor the safety of the treatment to ensure that it does not cause any harmful side effects. By participating in this trial, researchers hope to gather valuable information that could lead to better treatment options for individuals affected by Frontotemporal Dementia.